lynx   »   [go: up one dir, main page]
News & Perspective
Drugs & Diseases
CME & Education
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Today on Medscape
Business of Medicine
Medical Lifestyle
Science & Technology
Medical Students
Nurses
Pharmacists
Residents
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Wednesday, April 2, 2025
      News & Perspective Drugs & Diseases CME & Education Video Decision Point

      From theheart.org on Medscape

      Coverage from the

      American College of Cardiology (ACC) Scientific Session 2025

      March 29 - 31, 2025; Chicago, Illinois

      March 29 - 31, 2025 Chicago, Illinois

      Conference News

      Perspectives

       

      Popular News From ACC 2024

      • Novel PCSK9 Inhibitor Reduced LDL by 50% Novel PCSK9 Inhibitor Reduced LDL by 50% Lerodalcibep, a third-generation PCSK9 inhibitor, reduced LDL by more than 50% vs placebo in patients with or at a high risk for CVD in the phase 3 LIBerate-HR trial.
        Medscape Medical News, Apr 18, 2024
      • Semaglutide Beneficial in HFpEF Patients With Diabetes Semaglutide Beneficial in HFpEF Patients With Diabetes In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
        Medscape Medical News, Apr 07, 2024
      • Impella CP Improves Survival in STEMI, Cardiogenic Shock Impella CP Improves Survival in STEMI, Cardiogenic Shock Use of a microaxial flow pump led to a lower risk of death in patients with STEMI-related cardiogenic shock in the DanGer Shock trial, although with more adverse events.
        Medscape Medical News, Apr 07, 2024

      Previous Coverage

      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Manage Preferences Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      Editions
      English Deutsch Español Français Português
      All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
      Лучший частный хостинг